(±)-trans-1,2-Diaminocyclohexane - CAS 1121-22-8
Catalog: |
BB002878 |
Product Name: |
(±)-trans-1,2-Diaminocyclohexane |
CAS: |
1121-22-8 |
Synonyms: |
(1R,2R)-cyclohexane-1,2-diamine |
IUPAC Name: | (1R,2R)-cyclohexane-1,2-diamine |
Description: | (±)-trans-1,2-Diaminocyclohexane (CAS# 1121-22-8) is a reagent used in the thyroid receptor agonists for treatment of androgenetic alopecia. |
Molecular Weight: | 114.19 |
Molecular Formula: | C6H14N2 |
Canonical SMILES: | C1CCC(C(C1)N)N |
InChI: | InChI=1S/C6H14N2/c7-5-3-1-2-4-6(5)8/h5-6H,1-4,7-8H2/t5-,6-/m1/s1 |
InChI Key: | SSJXIUAHEKJCMH-PHDIDXHHSA-N |
Boiling Point: | 79-81 °C (15 mmHg) |
Melting Point: | 14-15 °C |
Purity: | 95 % |
Density: | 0.951 g/cm3 |
Appearance: | Colorless liquid |
Storage: | Keep in dark place, Inert atmosphere, Room temperature |
MDL: | MFCD00063747 |
LogP: | 1.61560 |
GHS Hazard Statement: | H314 (100%): Causes severe skin burns and eye damage [Danger Skin corrosion/irritation] |
Precautionary Statement: | P260, P261, P264, P272, P280, P301+P330+P331, P302+P352, P303+P361+P353, P304+P340, P305+P351+P338, P310, P321, P333+P313, P363, P405, and P501 |
Signal Word: | Danger |
Publication Number | Title | Priority Date |
US-2021184132-A1 | Compound, composition including the same, liquid composition, and organic electroluminescent device | 20191204 |
WO-2021107474-A1 | Compound and organic light-emitting device comprising same | 20191125 |
WO-2021095806-A1 | Particulate water absorbent and method for producing same | 20191112 |
US-2021122712-A1 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | 20191023 |
WO-2021081141-A1 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | 20191023 |
PMID | Publication Date | Title | Journal |
23001015 | 20121205 | Effect of synthetic eel calcitonin, elcatonin, on cold and mechanical allodynia induced by oxaliplatin and paclitaxel in rats | European journal of pharmacology |
22209842 | 20121201 | Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study) | Medical oncology (Northwood, London, England) |
22246215 | 20121201 | Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy | Investigational new drugs |
22270257 | 20121201 | Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer | Investigational new drugs |
22427209 | 20121201 | Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib | Medical oncology (Northwood, London, England) |
Complexity: | 62.9 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 2 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 114.115698455 |
Formal Charge: | 0 |
Heavy Atom Count: | 8 |
Hydrogen Bond Acceptor Count: | 2 |
Hydrogen Bond Donor Count: | 2 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 114.115698455 |
Rotatable Bond Count: | 0 |
Topological Polar Surface Area: | 52 Å2 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | -0.3 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Nitrogen Compounds
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS